These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26428517)

  • 1. Dissolution Similarity Requirements: How Similar or Dissimilar Are the Global Regulatory Expectations?
    Diaz DA; Colgan ST; Langer CS; Bandi NT; Likar MD; Van Alstine L
    AAPS J; 2016 Jan; 18(1):15-22. PubMed ID: 26428517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Approaches for Dissolution Similarity Assessment, Requirements, and Global Expectations.
    Abend AM; Zhang L; Fredro-Kumbaradzi E; Hoffelder T; Cohen MJ; Anand O; Delvadia P; Mandula H; Zhang Z; Kotzagiorgis E; Lum S; Pereira VG; Barker A; Lavrich D; Kraemer J; Sharp-Suarez S
    AAPS J; 2022 Mar; 24(3):50. PubMed ID: 35352186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro Dissolution Profiles Similarity Assessment in Support of Drug Product Quality: What, How, When-Workshop Summary Report.
    Suarez-Sharp S; Abend A; Hoffelder T; Leblond D; Delvadia P; Kovacs E; Diaz DA
    AAPS J; 2020 May; 22(4):74. PubMed ID: 32430592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical Considerations Concerning Dissimilar Regulatory Requirements for Dissolution Similarity Assessment. The Example of Immediate-Release Dosage Forms.
    Jasińska-Stroschein M; Kurczewska U; Orszulak-Michalak D
    J Pharm Sci; 2017 May; 106(5):1275-1284. PubMed ID: 28088455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scientific and regulatory standards for assessing product performance using the similarity factor, f2.
    Stevens RE; Gray V; Dorantes A; Gold L; Pham L
    AAPS J; 2015 Mar; 17(2):301-6. PubMed ID: 25669756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the Regulatory Divergence of Comparative Dissolution Requirements for Post-Approval Manufacturing Changes of Modified Release Solid Oral Dosage Forms.
    Langer C; Diaz DA; Van Alstine L; Bandi N; Fitzgerald S; Colgan S
    AAPS J; 2019 Nov; 22(1):2. PubMed ID: 31686262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FIP position paper on qualification of paddle and basket dissolution apparatus.
    Brown CK; Buhse L; Friedel HD; Keitel S; Kraemer J; Morris JM; Stickelmeyer M; Yomota C; Shah VP;
    AAPS PharmSciTech; 2009; 10(3):924-7. PubMed ID: 19609681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The International Conference on Harmonization common technical document--global submission format?
    Molzon JA
    Food Drug Law J; 2005; 60(3):447-51. PubMed ID: 16304749
    [No Abstract]   [Full Text] [Related]  

  • 9. Good manufacturing practice: the role of local manufacturers and competent authorities.
    Tomić S; Filipović Sučić A; Ilić Martinac A
    Arh Hig Rada Toksikol; 2010 Dec; 61(4):425-36. PubMed ID: 21183434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inspections: the international regulatory view.
    Turner JL
    PDA J Pharm Sci Technol; 1994; 48(4):180-1. PubMed ID: 7804815
    [No Abstract]   [Full Text] [Related]  

  • 11. Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence.
    Wiktorowicz M; Moscou K; Lexchin J
    Global Health; 2018 Aug; 14(1):86. PubMed ID: 30134929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A gamma process modeling approach for the comparison of dissolution profiles.
    Ng HKT; Ling MH; Chan PS
    Drug Dev Ind Pharm; 2018 Apr; 44(4):553-562. PubMed ID: 29139317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing Excipient Supplier Name and Address Changes in the Pharmaceutical Quality System.
    Rolke R; Ramnarine E; Vinther A; Sawant A
    PDA J Pharm Sci Technol; 2020; 74(2):286-288. PubMed ID: 32179712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Counterfeiting and piracy of pharmaceuticals.
    Grackin A
    IEEE Eng Med Biol Mag; 2008; 27(6):66-9. PubMed ID: 19004698
    [No Abstract]   [Full Text] [Related]  

  • 16. Regulatory forum opinion piece*: supporting the need for international harmonization of safety assessments for food flavoring substances.
    Konishi Y; Hayashi SM; Fukushima S
    Toxicol Pathol; 2014 Aug; 42(6):949-53. PubMed ID: 23881932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value and benefits of the International Conference on Harmonisation to drug regulatory authorities: advancing harmonization for better public health.
    Molzon JA; Giaquinto A; Lindstrom L; Tominaga T; Ward M; Doerr P; Hunt L; Rago L
    Clin Pharmacol Ther; 2011 Apr; 89(4):503-12. PubMed ID: 21326288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The American manufacturer's view on the EEC texts and harmonization.
    Draayer HA; Hilsabeck LJ; Miller RH
    Dev Biol Stand; 1992; 79():77-83. PubMed ID: 1286768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International Conference on Harmonisation; guidance on good manufacturing practice for active pharmaceutical ingredients; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Sep; 66(186):49028-9. PubMed ID: 12358036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International Conference on Harmonisation; Guidance on E16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure, and Format of Qualification Submissions; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2011 Aug; 76(155):49773-4. PubMed ID: 21834216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.